Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-cash Items: 2015-2025

Historic Non-cash Items for Seres Therapeutics (MCRB) over the last 10 years, with Sep 2025 value amounting to $2.3 million.

  • Seres Therapeutics' Non-cash Items fell 77.27% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 77.27%. This contributed to the annual value of $9.9 million for FY2024, which is 6.08% down from last year.
  • Per Seres Therapeutics' latest filing, its Non-cash Items stood at $2.3 million for Q3 2025, which was up 361.99% from $495,252 recorded in Q1 2025.
  • Seres Therapeutics' Non-cash Items' 5-year high stood at $19.9 billion during Q1 2022, with a 5-year trough of $495,252 in Q1 2025.
  • For the 3-year period, Seres Therapeutics' Non-cash Items averaged around $8.2 million, with its median value being $9.4 million (2023).
  • Its Non-cash Items has fluctuated over the past 5 years, first soared by 499,438.50% in 2022, then crashed by 99.96% in 2023.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Non-cash Items stood at $28.0 million in 2021, then slumped by 58.55% to $11.6 million in 2022, then skyrocketed by 41.70% to $10.0 million in 2023, then climbed by 0.66% to $15.3 million in 2024, then slumped by 77.27% to $2.3 million in 2025.
  • Its Non-cash Items stands at $2.3 million for Q3 2025, versus $495,252 for Q1 2025 and $15.3 million for Q4 2024.